Opportunity ID: 289602

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-DA-17-020
Funding Opportunity Title: Nicotinic Immune Modulation in the Presence of HIV-1 Infection (R01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards: 6
Assistance Listings: 93.279 — Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Oct 19, 2016
Last Updated Date:
Original Closing Date for Applications: Jan 17, 2017
Current Closing Date for Applications: Jan 17, 2017
Archive Date: Feb 17, 2017
Estimated Total Program Funding: $3,000,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Native American tribal governments (Federally recognized)
County governments
Independent school districts
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Public housing authorities/Indian housing authorities
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
Private institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
State governments
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Small businesses
For profit organizations other than small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The FOA encourages the submission of research project applications to determine nicotines modulatory effects on peripheral and central immune system functions in the presence of HIV-1 infection. Specifically, NIDA is particularly interested in projects exploring the ability of nicotine to produce anti-inflammatory and protective effects, and the translational potential of the new knowledge in attenuating HIV-induced pathologies and HIV-associated CNS complications such as neurological/cognitive disorders.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-17-020.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-D Use for due dates on or after May 25, 2016 PKG00228694 Dec 17, 2016 Jan 17, 2017 View

Package 1

Mandatory forms

289602 RR_SF424_2_0-2.0.pdf

289602 PHS398_CoverPageSupplement_3_0-3.0.pdf

289602 RR_OtherProjectInfo_1_3-1.3.pdf

289602 PerformanceSite_2_0-2.0.pdf

289602 RR_KeyPersonExpanded_2_0-2.0.pdf

289602 PHS398_ResearchPlan_3_0-3.0.pdf

Optional forms

289602 RR_Budget_1_3-1.3.pdf

289602 RR_SubawardBudget30_1_3-1.3.pdf

289602 PHS398_ModularBudget_1_2-1.2.pdf

289602 PHS_Inclusion_Enrollment_Report-1.0.pdf

289602 PHS_AssignmentRequestForm-1.0.pdf

2025-07-09T09:18:24-05:00

Share This Post, Choose Your Platform!

About the Author: